{
  "id": 19203639,
  "title": "Acadia Pharmaceuticals stock hits 52-week low at 18.24 USD",
  "url": "https://urgent.news/2026/11/09/acadia-pharmaceuticals-stock-hits-52-week-low-at-18-24-usd",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-09T19:32:09.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/acadia-pharmaceuticals-stock-hits-52week-low-at-1824-usd-93CH-5013058"
  },
  "original_language": "en",
  "account": "Acadia Pharmaceuticals Inc experienced a major setback as its stock hit a 52-week low of 18.24 USD, slightly above its 52-week low of 18.39 USD. The company's shares have plummeted over 20% year-to-date, trading at a low P/E ratio of 9.98 and an even lower PEG ratio of 0.28, indicating potential value. Analysts contend the stock is undervalued compared to its Fair Value, positioning it among those on the Most Undervalued list. The decline can be attributed to broader challenges in the pharmaceutical industry and waning investor confidence in the company's future prospects. However, 7 analysts have recently revised their earnings upward for the upcoming period, and Acadia maintains more cash than debt on its balance sheet. For investors seeking a more thorough understanding, a Pro Research Report is available, analyzing both Acadia and 1,400+ other US equities. Despite the recent woes, the company posted impressive third-quarter 2026 results, surpassing expectations. Adjusted earnings of $0.31 per share significantly exceeded the projected $0.20, while revenue reached $342 million, outpacing forecasts of $332.42 million. This success is largely attributed to record sales of DAYBUE, which increased by 39% year-over-year to $140 million. NUPLAZID also saw a 12% increase on an adjusted basis, contributing $202 million in net sales. Acadia has lowered its full-year 2026 revenue guidance to between $1.265 billion and $1.295 billion. RBC Capital has raised its price target for the stock to $38 from $36, maintaining an Outperform rating, likely due to DAYBUE's continued growth, particularly the successful STIX formulation. This suggests potential for further expansion in the U.S. market as the company aims to convert existing patients and those who had previously stopped treatment.",
  "summary": null,
  "key_points": [
    "Acadia Pharmaceuticals stock reached 52-week low of 18.24 USD",
    "Company's shares declined over 20% year-to-date",
    "NUPLAZID sales increased 12% on adjusted basis"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}